Jonathan J. Darrow - Concepedia

Author

Jonathan J. Darrow

Brigham and Women's Hospital ORCID

Also Known As

Jonathan Darrow, Jonathan J Darrow, Jonathan J. Darrow

122

Publications

2.4K

Citations

H-Index

115

Concepts

All Affiliations

Brigham and Women's Hospital Harvard University Bentley University University of Calgary Yale University

About

Jonathan J. Darrow is an author at Brigham and Women's Hospital specializing in medicine, pharmacology, and health policy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Business	2	2	68
2	Education	1	1	20
3	Engineering	1	1	41
4	Health Sciences	1	1	17
5	Humanities	1	1	10

Jonathan J. Darrow

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
FDA Approval and Regulation of Pharmaceuticals, 1983-2018 Jonathan J. Darrow, Jerry Avorn, Aaron S. Kesselheim JAMA	2020	336
Luxturna: FDA documents reveal the value of a costly gene therapy Jonathan J. Darrow Drug Discovery Today Gene TherapiesNovel TherapyIn Vivo Gene TherapyGeneticsPharmacology	2019	201
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study Aaron S. Kesselheim, Bo Wang, Jessica M. Franklin, BMJ	2015	184
FDA Regulation and Approval of Medical Devices: 1976-2020 Jonathan J. Darrow, Jerry Avorn, Aaron S. Kesselheim JAMA	2021	151
Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs Jonathan J. Darrow, Ameet Sarpatwari, Jerry Avorn, New England Journal of Medicine Expanded AccessDrug PolicyInvestigational DrugsLawPharmacotherapy	2015	145
New FDA Breakthrough-Drug Category — Implications for Patients Jonathan J. Darrow, Jerry Avorn, Aaron S. Kesselheim New England Journal of Medicine Drug RepositioningHealth PolicyDigital TherapeuticsMedicinePharmacological Issue	2014	116
Efficacy, Safety, and Regulatory Approval of Food and Drug Administration–Designated Breakthrough and Nonbreakthrough Cancer Medicines Thomas J. Hwang, Jessica M. Franklin, Christopher T. Chen, Journal of Clinical Oncology Chemoprevention StrategyCancer ManagementDrug Administration–designated BreakthroughBreakthrough Therapy ProgramPharmacotherapy	2018	99
The FDA’s Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016 Thomas J. Hwang, Jonathan J. Darrow, Aaron S. Kesselheim JAMA Preclinical TherapeuticsPharmacotherapyUs FoodTreatment DevelopmentClinical Development Times	2017	77
The FDA Breakthrough-Drug Designation — Four Years of Experience Jonathan J. Darrow, Jerry Avorn, Aaron S. Kesselheim New England Journal of Medicine Breakthrough-therapy DesignationTranslational MedicineDrug RepositioningPharmaceutical ResearchSubstantial Improvement	2018	58
An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19 Aaron S. Kesselheim, Jonathan J. Darrow, Martin Kulldorff, Health Affairs Surrogate MarkersImmunologyVaccine HesitancyCovid-19Preventive Medicine	2020	55

Page 1